Showing results (1091-1100 of 1,193) with videos related to

Sort By:
Pageof 120
JCO Precision Oncology|December 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute LeukemiaHannah Goulart, Farhad Ravandi, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Nature Communications|January 18, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsHaijiao Zhang, Samantha Savage, Anna Reister Schultz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Nature Communications|July 12, 2018
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypesKoichi Takahashi, Feng Wang, Kiyomi Morita, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple MyelomaNatthakan Thongon, Feiyang Ma, Pamela Lockyer, et al.
Haematologica|May 7, 2026
Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatmentRami Komrokji, Zaker Schwabkey, Zena Komrokji, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Blood Cancer Discovery|April 27, 2023
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid MalignanciesCurtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Pageof 120